LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 Est; Lowers FY2026 Sales Guidance from $277.000M-$283.000M to $274.300M-$278.300M vs $279.948M Est

LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 analyst estimate. Lowers FY2026 sales outlook from $277.000 million-$283.000 million to $274.300 million-$278.300 million vs $279.948 million estimate.